Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $79.58 in the prior trading day, Viking Therapeutics Inc (NASDAQ: VKTX) closed at $76.43, down -3.96%. In other words, the price has decreased by -$3.96 from its previous closing price. On the day, 4.02 million shares were traded. VKTX stock price reached its highest trading level at $80.3783 during the session, while it also had its lowest trading level at $75.665.
Ratios:
Our goal is to gain a better understanding of VKTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 29.48 and its Current Ratio is at 29.48. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on March 26, 2024, Reiterated its Outperform rating but revised its target price to $138 from $116 previously.
On March 07, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $110.
Oppenheimer reiterated its Outperform rating for the stock on February 28, 2024, while the target price for the stock was revised from $46 to $116.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 09 ’24 when Lian Brian sold 45,000 shares for $29.90 per share. The transaction valued at 1,345,500 led to the insider holds 2,139,882 shares of the business.
Lian Brian sold 269,079 shares of VKTX for $7,230,784 on Feb 08 ’24. The President & CEO now owns 2,184,882 shares after completing the transaction at $26.87 per share. On Feb 08 ’24, another insider, Rouan Sarah Kathryn, who serves as the Director of the company, sold 25,000 shares for $28.05 each. As a result, the insider received 701,250 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VKTX now has a Market Capitalization of 8427783168 and an Enterprise Value of 7466004480.
Stock Price History:
The Beta on a monthly basis for VKTX is 1.12, which has changed by 2.526996 over the last 52 weeks, in comparison to a change of 0.23568535 over the same period for the S&P500. Over the past 52 weeks, VKTX has reached a high of $99.41, while it has fallen to a 52-week low of $8.28. The 50-Day Moving Average of the stock is 9.42%, while the 200-Day Moving Average is calculated to be 160.64%.
Shares Statistics:
The stock has traded on average 6.47M shares per day over the past 3-months and 2937310 shares per day over the last 10 days, according to various share statistics. A total of 110.27M shares are outstanding, with a floating share count of 101.35M. Insiders hold about 8.08% of the company’s shares, while institutions hold 68.86% stake in the company. Shares short for VKTX as of 1713139200 were 11147825 with a Short Ratio of 1.72, compared to 1710460800 on 11141879. Therefore, it implies a Short% of Shares Outstanding of 11147825 and a Short% of Float of 13.639999999999999.
Earnings Estimates
The current assessment of Viking Therapeutics Inc (VKTX) involves the perspectives of 11.0 analysts closely monitoring its market dynamics.On average, analysts expect EPS of -$0.26 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.32, while EPS last year was -$0.19. The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.2 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$0.85 and -$1.27 for the fiscal current year, implying an average EPS of -$1.12. EPS for the following year is -$1.55, with 10.0 analysts recommending between -$0.96 and -$2.11.
